^(111)In-DTPA-D-Phe^1-octreotide的动物实验  

Animal experiment of ^(111)In-DTPA-D-Phe^1-octreotide

作　　者：王凡[1] 陈方[2] 肖伦[1] 樊红强[1] 金小海[1] 王翌善[1] 陈大明[1] 白宏升[1] 李家秀[3] 刘琳[3] 

机构地区：[1]中国原子能科学研究院同位素研究所,北京102413 [2]中国医学科学院中国协和医科大学北京协和医院,北京100730 [3]中国医学科学院肿瘤研究所,北京100021

出　　处：《核技术》1998年第5期293-296,共4页Nuclear Techniques

基　　金：国家科委"九五"攻关项目

摘　　要：Somatostatin受体阳性肿瘤显像剂111In－DTPA－D－Phe1－octreotide在体内降解产物为111In－DTPA，给药后3h血中111In－DTPA占血中放射性的50％，尿中为40％。正常鼠与载胰腺癌裸鼠的动物实验表明：该显像剂的血液清除很快，注射后10min血液的％ID／g为注射后1min的50％；放射性主要从泌尿系统排泄，给药后4min膀胱显影，至30min双肾和膀胱的放射性含量达50％ID；T／B比值在给药后逐渐增高，至24h可达7．92；给药后0．5－24h均可进行载胰腺癌裸鼠模型上的肿瘤阳性显像，24h时相的图像质量最佳。The animal experiments of a novel somatostatin receptor-positive tumorsimaging agent, 111In- DTPA - D - Phe1 - octreotide, has been described. Biologicalproperties were evaluated by dynamic and static γ images of somatostatinreceptor-positive tumors in nude mice bearing pancreatic carcinoma. Theradiocomponent of 111In-DTPA, which came from 111In-DTPA-D-Phe1-octreotidedecomposition, showed 50% of radioactivity in blood and 40% in urine at 3hpostinjection. Rapid blood and urine clearance, and high T/B ratio (7.92 up to 24hpostinjection) were observed. The images of somatostatin receptor-positive tumorscould be obtained during 0.5- 24h after administration but the best one would be at24h.

关 键 词：受体阳性肿瘤 核素标记 肿瘤 显像剂 动物实验 

分 类 号：R817[医药卫生—影像医学与核医学]